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Summary The prevalence of nausea and emesis among a series of out-patients (n = 95) receiving mainly mild-
to moderately-emetic cytotoxics, was assessed, along with levels of psychological morbidity. Particular focus
was given to the rates of psychologically-based (anticipatory) nausea and emesis. Results indicated that 23%
of patients experienced anticipatory nausea and the majority reported that this occurred before at least half of
the previous treatment cycles. Both emetic challenge ofchemotherapy regimen and younger age were linked to
this anticipatory effect. The data clearly indicated that nausea and emesis, both post-treatment and in
anticipation of treatment, carried a psychological cost with anxiety being highest in those experiencing
anticipatory nausea and/or emesis. The role of anxiety in the aetiology of psychologically-based nausea and
emesis was not evaluated and it is considered that a prospective study is needed to clarify the exact
contribution of psychological factors in the incidence of both post-treatment and anticipatory side-effects.
Nausea and emesis are the most commonly reported side-
effects of cancer chemotherapy [CT] (Coates et al., 1983) and
may influence the patients' physical state causing appetite
and weight loss and general weakness, and their mental state
by producing feelings of apprehension, depression and loss of
control. Not surprisingly, the extent of nausea and emesis
experienced is strongly related to how difficult the patient
finds chemotherapy and tackling this side-effect is a major
challenge in oncology.
There is also an increasing literature showing that some
patients receiving CT develop psychologically-based nausea
and emesis (Watson & Marvell, 1991). Although this may
occur before, during or after administration of CT most
studies examine anticipatory symptoms, as the psychological
effect is more difficult to distinguish from purely drug-related
effects at other times. However, post-treatment nausea and
emesis which is out of proportion to the emetic challenge of
the CT drugs may well indicate a psychological element and
this effect is less well researched.
Although occurring less commonly than post-treatment
nausea and emesis, the importance of the anticipatory side-
effect lies in its intractability once established and the fact
that it may continue after CT administration has ceased, with
some patients feeling nauseous when they return for follow-
up out-patient appointments (Hughson & Cooper, 1988).
Furthermore, it is assumed that with the advent of the
5-hydroxytryptamine3 (5-HT3) antagonists, not only will
post-treatment side-effects be controlled, but anticipatory
symptoms should become a thing of the past. However,
control using 5-HT3 drugs is not always complete (Jones et
al., 1991; Smyth et al., 1991) and as yet there are no pub-
lished studies which examine the prevalence of an
anticipatory nausea and emesis response where 5HT3, drugs
were used, although clearly such studies are needed.
The most widely accepted explanation for anticipatory/
psychologically-based nausea and emesis is that it is a condi-
tioned (i.e. learnt) response. Neutral stimuli present at the
time of CT administration, and associated with the drug-
induced effect, acquire the ability to trigger nausea and/or
emesis during subsequent treatment cycles, even when the
drug has not yet been administered. In psychological terms
this is a very simple learning paradigm and the effect has also
been observed in sub-humans.
A number of studies have drawn attention to the possible
role of anxiety as a contributory factor (Altmaier et al., 1982;
Andrykowski et al., 1985; Nerenz et al., 1986). It is
intuitively appealing to explain psychologically-based nausea
and emesis in terms of 'nerves' yet it is clear from Andrykow-
ski's recent review (1990) that no conclusions can yet be
reached with regard to any causal model invoking anxiety as
a factor. It is also not clear what levels of psychological
morbidity exist among patients experiencing these side-effects
and whether, for instance, depression is widely evident.
Other possible risk factors potentiating psychologically-
based nausea and emesis include a tendency to travel sickness
in adulthood, and younger age (Morrow et al., 1991). The
clearest contributor, however, is thought to be severe and
long-lasting nausea and emesis following previous CT
infusions. Thus it is likely that the toxicity of the drug regime
will determine the probability of patients developing the
anticipatory side-effect.
Food aversions and changes in food preference are also
considered to be relatively common among patients receiving
cytotoxics but prevalence rates are unclear. The aetiology of
such complaints may stem from taste bud deficits caused by
certain cytotoxics or disruption to diet caused by bowel
obstruction. Tumour released toxins may also cause changes
in eating behaviour. However, food aversions can also arise
as a result of psychological conditioning. Post-treatment
nausea and emesis following the ingestion of particular foods
or in the presence of particular food smells can result in a
learnt aversion to that food. It has been demonstrated (Bern-
stein, 1982; Bernstein, 1985) that as little as one 'pairing'
event can establish this learnt aversive response.
The aim of the present study was to examine the
prevalence of anticipatory nausea and emesis and any possi-
ble association of these responses with suggested risk factors
such as; the emetic challenge of the CT regimen, level of
anti-emetic cover, concurrent anxiety and depression, predis-
position to travel sickness, and age. We also examined the
rate of food aversion onset and any possible associations
with the preceding variables. Levels of psychological mor-
bidity, i.e. depression and anxiety, were examined throughout
the whole sample and prevalence rates across three groups
compared; (i) those reporting no experience of nausea and/or
emesis throughout their CT treatment, (ii) those with post-
treatment symptoms only, and (iii) those patients with
anticipatory nausea and/or emesis.
These factors were examined in a series of patients receiv-
ing intravenous (IV) CT infusions on an out-patient basis
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because such patients are generally representative of the
majority of those receiving chemotherapy. It was considered
that by clarifying these associations better management of
psychological problems, arising from CT-related side-effects,
might be achieved.
Method
Sample
An unselected series of 105 out-patients attending the Royal
Marsden Hospital for IV infusion of cytotoxics was surveyed
providing the following criteria were fulfilled: age 18 or over,
English speaking, no evidence of gastro-intestinal obstruction
or brain tumour, completion of at least one cycle of
chemotherapy and consultant's permission.
Procedure
Patients completed an evaluation of nausea and emesis using
the Morrow Assessment of Nausea and Emesis - MANE -
(Morrow, 1984). This is a patient-report measure which
separates symptoms of both post-treatment and anticipatory
nausea and emesis into three distinct topologic elements;
frequency, severity and duration, as well as asking patients to
indicate when symptoms were at their worst. Where there
was evidence of anticipatory symptoms, time of onset prior
to CT infusion was recorded, along with any evidence for cue
reactivity (i.e. triggering of nausea and/or emesis by stimuli
such as needles, sight of IV equipment and so on). Prevalence
of pre-existing travel sickness in adulthood was assessed
along with food aversions of recent onset. Psychological
morbidity was assessed using the Hospital Anxiety and
Depression [HAD] scale (Zigmond & Snaith, 1983), a mea-
sure developed specifically for medical populations. Medical
data included; primary diagnosis, disease stage, number of
CT cycles, prescribed cytotoxics and anti-emetics. An emetic
challenge classification of CT regimen was devised using
guidelines suggested by Cohen et al. (1986) and Cunningham
(1990) dividing drugs into high, moderate or mild emetic
challenge (Table I). Since 80% of the sample were on multi-
ple drug regimens, evaluation ofchallenge was determined by
the most emetogenic agent in the protocol.
Anti-emetic cover was ascribed a high, moderate or low
value depending on whether the patient was prescribed a
5HT3 antagonist (high), an IV anti-emetic cocktail, but not a
5HT3 (moderate) or oral anti-emetic only (low). All patients
were assessed immediately prior to their next infusion and at
least one week after their previous infusion (the latter allows
for control of any confounding of drug-related versus
psychologically-based effects).
Statistical methods
The sample was divided into three groups of patients; group
I, patients without nausea and emesis; group II, patients with
post-treatment nausea and/or emesis only and group III,
patients with anticipatory nausea and/or emesis. These three
groups were then compared in terms of the variables
recorded.
To avoid multiple comparisons all P-values quoted were
calculated from tests for trend. In these tests the null
hypothesis of equivalence between groups was tested against
the alternative that the patients in group III showed greater
symptoms than those in group II who, in turn, showed
greater symptoms than those in group I. Continuous var-
iables (age, number of infusions, HAD anxiety and depres-
sion) were analysed using linear contrasts from a simple
analysis of variance. (Non-parametric Kruskall-Wallis tests
were performed to check the robustness of the analysis of
variance to assumptions or normality. These tests gave very
similar results to the parametric tests and are not presented.)
Categorical variables (all others) were analysed using chi-
square tests for trend. All probability values are based on
univariate tests and are not adjusted for other variables.
Results
The sample include 91% (n = 95) of the total number of
eligible patients with ten patients being excluded because CT
infusions had commenced before there was an opportunity to
make the planned evaluation. Cytotoxic regimens of the
study sample are given in Table II.
Demographic and medical details are given in Table III.
the mean age of the sample was 50 (range 19-79 years) with
a 2:1 female to male ratio. There were approximately equal
numbers of patients with early (Stage I or II) and advanced
(Stage III and IV) disease. There were no differences between
the three groups on these variables with the exception of age,
where there was a significant trend (P = 0.003), in line with
the previously observed link between younger age and
anticipatory symptoms reported elsewhere.
Comparisons across chemotherapy groups (i.e. high,
medium or low emetic challenge) showed no significant age
differences (P = 0.54), indicating that CT toxicity was no
greater in younger patients.
The trend for sex was not statistically significant but
patients with anticipatory symptoms were predominantly
female (19/22).
Antiemetics were prescribed routinely and at the time of
survey 13 patients were receiving a 5HT3 antagonist
(Ondansetron) given IV with CT and then orally for 3-5
days, 57 patients dexamethasone and/or metoclopramide IV
followed through orally, 13 had this as oral medication only
and 12 had no antiemetic medication. Three patients had
also received Lorazepam in addition to an antiemetic.
Post-treatment nausea and emesis
Seventy patients (73%) experienced post-treatment nausea
during preceding cycles and for 37 (38%) this had occurred
after every or most of their cytotoxic infusions. Thirty one
patients (33%) had post-treatment emesis and for nine this
had occurred after every or most infusions. Only one patient
considered the post-treatment symptoms to be intolerable.
However, 38 (40%) of the sample rated this nausea as
Table I Classification of cytotoxic drugs
challenge
according to emetic
High Moderate Mild
Cisplatin Actinomycin Vincristine
Dacarbazine Cyclophosphamide 5 Fluorouracil
Carboplatin Doxorubicin Methotrexate
Epirubicin Chlorambucil
Etoposide Bleomycin
Mitomycin-C Melphalan
Vinblastine
Vincristine
High: 90% - 100% probability of inducing emesis; Moderate: 50%
probability associated with these agents; Mild: Rarely causes emesis.
Table II Cytotoxic regimens of the study sample
Drug protocol n
Fluorouracil (5FU) 17
Mitomycin C, Methotrexate, Mitozantrone (3Ms) 33
Vincristine, Epirubicin, Etoposide,
Prednisolone (VEEP) 10
Vinblastine, Procarbazine, Doxorubicin,
Prednisolone (C-VAMP) 4
Vinblastine 1
Vincristine, Epirubicin, Cyclophosphamide (VEC) 6
Cyclophosphamide, Vincristine, Doxorubicin,
Methylprednisolone (CHOP) 13
Carboplatin 1
Dacarbazine 1
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moderate or severe and 20 (21%) had a similar rating for
post-treatment emesis. Patients were asked to indicate when
nausea and/or emesis was at its worst. No patient indicated
that the period during treatment was worst, rather these
symptoms tended, for the majority, to be at their worst some
24 h or more after CT infusion. The average duration of the
post-treatment side-effects from time of onset was 48 and
14 h for nausea and emesis, respectively.
Anticipatory nausea and emesis
Twenty two patients (23%) experienced nausea in anticipa-
tion of treatment and for most of these (17/22) this occurred
during the four hours immediately prior to infusion. Nine of
these 22 patients had anticipatory nausea before every or
most infusions and a further ten patients experienced this
before about half of their treatments. Thus, 20% of all
patients surveyed experienced anticipatory nausea before at
least half of their preceding infusions. Only four patients
experienced anticipatory emesis, primarily during the 4 h
prior to CT infusion, and for three of these this occurred
before at least half of their preceding treatments.
All patients with anticipatory symptoms had experienced
post-treatment nausea and/or emesis, except one patient,
being treated for advanced breast cancer, who reported no
post-treatment nausea and/or emesis during the present treat-
ment cycles but reported having experienced severe emesis
during her treatment for primary disease when she had
received adjuvant chemotherapy.
The number of CT infusions was not significantly different
between the three groups (Table IV). Tests for trend between
the groups in relation to the emetic challenge of the CT
regimens showed a significant effect (P = 0.04) with patients
in the mild emetic challenge group being less likely to
develop both post-treatment and anticipatory nausea and
emesis than those in the medium to high groups. There was a
significant trend (P = 0.036) depending on antiemetic cover
showing that as symptoms of nausea and emesis increased
patients were more likely to be receiving high to moderate,
rather than low or absent cover. The prevalence of food
aversions was also significantly different between the three
groups with a clearly increasing trend depending on increas-
ing symptoms of nausea and/or emesis (P = 0.014). Five of
the 23 (22%) patients reporting no nausea or emesis
confirmed the onset of a food aversion compared to 17 of 50
(34%) with post-treatment symptoms and 13 of 22 (59%)
with anticipatory symptoms. Cue reactivity (i.e. the tendency
for nausea and/or emesis to be triggered by treatment-related
accoutrements) was reported by ten patients of those 22 with
anticipatory symptoms. The tendency to be travel sick in
adulthood was reported in 12 (13%) of the sample as a
whole with no significant differences between the three
groups.
Psychological morbidity
Levels of depression and anxiety, assessed using the Hospital
Anxiety and Depression[HAD] scale were evaluated for the
Table III Demographic and medical details
aGroup I Group II Group III Totals
(n = 23) (n = 50) (n = 22) (n = 95) P-value
Age: Mean (s.d.) 57(10.4) 49(14.5) 45(14.3) 50(14.1) 0.003
Range 39-75 21-79 19-71 19-79
Sex: Male 9 19 3 31 0.102
Female 14 31 19 64
Site: Breast 9 18 15 42 0.076b
Lymphomas 3 14 6 23
Colon 6 7 1 14
Myeloma 4 4 0 8
Others 1 7 0 8
Stage: I 5 18 4 27 0.981C
II 7 14 7 28
III/IV 11 18 11 40
aGroup I: Nausea and emesis absent; Group II: Post-treatment nausea and emesis only; Group III:
Anticipatory nausea and emesis. bBreast vs all others. cStage I/II vs III/IV.
Table IV Treatment-related effects
Group I Group II Group III Totals
(n = 23) (n = 50) (n = 22) (n = 95) P-value
Cytotoxics:
Emetic challenge
Mild 7 9 1 17 0.040a
Moderate 16 40 20 76
High 0 1 1 2
Number infusions
Mean (s.d.) 8(6.5) 7(4.4) 6(4.4) 7(5.0) 0.179
Median (range) 5(1-25) 6(2-19) 4.5(2-23) 5(1 -25)
Antiemetic cover
High 2 9 2 13 0.036b
Moderate 12 27 18 57
Low 3 8 2 13
None 6 6 0 12
Food aversion
Yes 5 17 13 35 0.014
No 17 29 8 54
Not known 1 4 1 6
Travel sick
Yes 2 6 4 12 0.468
No 21 44 18 83
aMild emetic challenge vs moderate/high. bHigh/moderate antiemetic cover vs low/none.ANTICIPATORY NAUSEA AND EMESIS, AND PSYCHOLOGICAL MORBIDITY
Table V Levels of psychological morbidity according to extent of nausea and emesis
Group I Group II Group III Totals
(n = 23) (n = 50) (n = 22) (n = 95) P-value
HAD anxiety
Mean (s.d.) 2.9(2.6) 5.4(3.3) 6.5(3.4) 5.1(3.4) <0.001
Number of 'cases':
Absent ( 7) 21 35 18 74
Borderline (8-10) 2 11 2 15
Present (>I1) - 4 2 6
HAD depression
Mean (sd) 3.7(3.1) 5.4(4.3) 5.5(3.5) 5.0(3.9) 0.111
Number of 'cases':
Absent ( <7) 20 37 14 71
Borderline (8-10) 3 9 6 18
Present (> I 1) - 4 2 6
three groups. A test for trend (Table V) indicated
significantly increasing anxiety (P = 0.001) across the three
groups with those patients experiencing anticipatory symp-
toms showing the highest level followed by patients with
post-treatment symptoms only and those with no symptoms
of nausea and/or emesis being least anxious. This trend was
not observed for depression although both groups experienc-
ing nausea and/or emesis had higher mean scores than those
without these side-effects.
The significant trend for younger age to be associated with
increased symptoms of nausea and emesis was mirrored in
scores for anxiety. A comparison of patients below 50 years
with those of 50 years or above indicated a significantly
higher mean score for anxiety (5.9 vs 4.3, P = 0.020). This
effect was not observed for depression. Hence, younger
patients report greater anxiety and this is most likely linked
with the reporting of more symptoms of nausea and/or
emesis.
Psychological morbidity was also assessed in terms of
number of clinical 'cases'. In this instance a 'case' represents
symptoms of anxiety or depression at a clinically significant
level. The HAD scale scores have a range from 0-21 and the
cut-off score for defining 'caseness' (Zigmond & Snaith, 1983)
was taken as > 11 for both anxiety and depression.
Borderline 'cases' were those scoring between 8-10 inc-
lusive and scores of 7 or less indicated a non-case or absence
of a clinically significant depression or anxiety. There were
no cases within the patients who had been free of nausea and
emesis throughout previous treatment cycles and only five
identified borderline cases. Similar percentages of cases were
observed for the patients experiencing post-treatment (8%)
and anticipatory (9%) side-effects, i.e. 4/50 and 2/22, respec-
tively for both anxiety and depression. For 'borderline cases'
the percentages for anxiety were 22% and 9% for patients
with post-treatment and anticipatory symptoms respectively,
and for depression were 18% and 27%. Combining the
number of borderline and clear cases for both groups
experiencing some nausea and emesis the percentages in the
group as a whole for anxiety (20%) are similar, and for
depression (22%) higher, than levels reported elsewhere in a
survey of recently diagnosed patients taken from the same
hospital (Greer et al., 1992), but both are slightly lower than
the numbers observed in breast cancer patients with
advanced disease (Hopwood et al., 1991). However, it is clear
that patients without the nausea and emesis side-effects
experience an extremely low level of psychological morbidity.
The challenge would be to try and bring psychological mor-
bidity, in patients with side-effects, down to the level of those
free of nausea and emesis and thereby improve quality of life
in these patients.
Discussion
The most striking finding from this study is the high pre-
valence rate for both post-treatment and anticipatory nausea
in this sample of out-patients receiving mainly mild to
moderately toxic drugs; 73% with post-treatment and 23%
with anticipatory nausea. Rates of emesis were lower; 33%
and 4% for post-treatment and anticipatory symptoms, res-
pectively. Nausea and emesis were, as expected, related to the
emetic challenge of the drug regimen for both post-treatment
and anticipatory symptoms. The anticipatory effect itself was
linked to the prevalence of nausea and emesis during pre-
ceding cycles and an emetic response of greater severity
following preceding treatments seemed to be a more crucial
factor than the frequency or duration of emesis.
It is possible that some symptoms of nausea go undetected
by oncology staff as onset in the present study more often
occurred after patients had left hospital. The effect for anti-
emetic control was interesting. More powerful antiemetic
control tended to be in use, at the time of survey, for those
patients experiencing nausea and emesis both post-treatment
and in anticipation of treatment. Bearing in mind that
antiemetics were in routine use across the sample one explan-
ation might be that antiemetic control is stepped up as
side-effects persist, however this needs to be examined pro-
spectively.
A trend toward younger age was observed in those patients
experiencing nausea and emesis and this has been reported
elsewhere in the literature (Cohen et al., 1986; Fetting et al.,
1983). The reason for this was unclear. Cohen and colleagues
(1986) questioned whether younger patients might be more
sensitive to the unpleasant side-effects of treatment or wheth-
er they conditioned more easily. It may be that younger
patients receive more aggressive treatments but this explana-
tion is not supported by the data here or elsewhere (Cohen et
al., 1986; Morrow, 1982). Morrow suggested that age seemed
to have an indirect rather than a direct effect on anticipatory
nausea and that this might possibly be mediated by higher
levels of anxiety. Data from the present study certainly
indicated that anxiety (but not depression) was higher in
younger patients, although direction of causality for anxiety
and anticipatory nausea and emesis was not examined in the
present cross-sectional study. As yet the reason for an age
effect is unclear and requires further investigation. Given the
increasing evidence for this age effect, however, it is likely
that younger patients (i.e. those <50 years) will need to be
considered for a first-line antiemetic.
No clear relationship could be established in the present
study between the pre-existing tendency toward travel sick-
ness and the anticipatory effect as observed elsewhere (Mor-
row et al., 1991), indeed the rate observed was low overall;
only 13% of the sample reported travel sickness. For almost
half of those patients experiencing anticipatory nausea there
was reported cue reactivity, with this side-effect being trig-
gered by the sights, sounds or smells associated with hospital
and CT. Such patients can be helped to control anticipatory
symptoms by devising means of cue disruption (for example
hospital smells can be disguised by competing smells such as
perfume).
It is important to say that only one patient reported the
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post-treatment symptoms as being intolerable. Against this
needs to be balanced the evidence that post-treatment and
anticipatory symptoms, where they occur, are not a rarity
but are frequent across the treatment cycles and the cost in
psychological terms is clear. Patients with post-treatment and
anticipatory side-effects reported more concurrent anxiety
than those without these treatment side-effects.
We cannot rule out the possibility that this effect may be
accounted for by pre-existing differences between the groups,
however, a more likely explanation would be that the
psychological morbidity is closely related to the treatment
side-effects experienced. This requires further investigation.
The present study did not assess the patients' expectations
about being or feeling sick and whether this might be a
causal element. The cross-sectional design prevented such an
evaluation. There is recent evidence, however, to suggest that
expectations play a significant role in both post-treatment
and anticipatory nausea and emesis (Haut et al., 1991). The
authors concluded from their small (n = 36) out-patient study
that 'Regression analysis revealed that the patients' expecta-
tions of how severe the nausea and vomiting would be,
consistently accounted for unique variance beyond phar-
macologic factors in predicting the frequency and severity of
these symptoms'. Their findings implied that oncologists need
to consider patients' expectations when prescribing
antiemetics. It also places oncologists in somewhat of a cleft
stick, of course, about the information given to patients.
Patients need to be informed oftreatment side-effects but this
information, of itself, may influence expectations and contri-
bute to side-effects. A positive attitude on the part of the
oncologist regarding control of side-effects may therefore
play an important role in helping patients cope with treat-
ment, in addition to any pharmacologic control of side-
effects.
At present there is a certain amount of debate about the
use of 5HT3 antagonists in the control of emesis (Editorial,
Lancet 1991), either alone or in combination with other
drugs such as dexamethasone. The effect on nausea is less
well researched, being more difficult to evaluate. However,
complete control of nausea and emesis is not achieved in
every patient (Jones et al., 1991; Smith et al., 1991; Smyth et
al., 1991) and it would be worthwhile to examine the
prevalence of anticipatory nausea and emesis where a 5HT3
anti-emetic is in use. The low numbers of patients on this
type of anti-emetic, in the present study, precluded any
detailed examination of these effects. The possibility that
non-medical variables such as anxiety and age contribute to
post-treatment side-effects needs to be considered and studied
further. The trend toward younger age in those patients with
increased symptoms of nausea is suggestive of a risk factor.
Further investigation using a prospective design would be
helpful. For anticipatory side-effects there was a clear and
predicted link to emetogenic challenge of cytotoxics and the
occurrence of nausea and emesis during previous cycles. The
psychological cost was clear and may have an important
effect on treatment compliance. It would be worthwhile to
examine these factors prospectively. If Haut and colleagues
(1991) are correct, simple psychological expediencies may be
capable of helping to reduce some of these side-effects
observed. This requires investigation.
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